With two years of experience selling Alzheimer’s disease antibody Leqembi so far under Eisai’s belt, the Japanese drugmaker ...

BB-1701 has survived Eisai’s decision not to option the HER2-directed antibody-drug conjugate. | BB-1701 has survived Eisai’s ...

Eisai and Biogen’s Alzheimer’s disease therapy Leqembi is due to be launched in Japan, its second market, on 20th December, and will be priced quite a lot lower there than in the US.

More and more pharma companies are looking "beyond the pill" when it comes to providing care for patients, few more so than Eisai, which is developing a package of products and services in Japan ...

Japan's Nikkei Stock Average closed 0.3% higher at 35725.87 as gains in the heavy industry and video game shares offset the ...

TOKYO -- Japanese drugmaker Eisai's share price is hovering around a 10-year low of 4,300 yen, weighed down by poor U.S. sales of its much-touted Alzheimer's treatment Leqembi and the company's ...

TOKYO, Mar 5, 2025 - (JCN Newswire) - Sato Pharmaceutical Co., Ltd. and Eisai Co., Ltd. announced today that they will conclude their co-promotion based on the co-promotion agreement in Japan ...

January 24, 2025 Merck, Eisai's combination drug fails in late-stage trial for esophageal cancer Merck and Japan-based Eisai said on Friday a combination of their therapies failed to extend the ...

Eisai & Biogen update on regulatory review of MAA for lecanemab for early Alzheimer’s disease by the European Commission: Tokyo Wednesday, April 2, 2025, 16:00 Hrs [IST] Eisai C ...